SEC 13F Intelligence

Managers / Q2 2021 · view latest →

HighVista Strategies LLC

CIK 0001335325 · 200 CLARENDON STREET, 50TH FLOOR, BOSTON, MA, 02116 · 617-406-6500

Reported Value
$141M
Q2 2021
Positions
116
Filings on Record
30
2019–present window
Filed
Aug 16, 2021
original filing

Summary

Highvista Strategies LLC reported $141M in U.S.-listed holdings across 116 positions for Q2 2021.

The portfolio is heavily concentrated: DELL alone accounts for 25.1% of reported value.

Compared with Q1 2021, the fund opened 37 new positions and exited 46.

Portfolio Metrics

Turnover
+26.3%
vs prior filed quarter
Top-10 Concentration
+55.7%
share of reported value
Largest Position
+25.1%
Dell Technologies
New / Exited
37 / 46
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $116MQ4 ’18Q1 ’19: $123MQ2 ’19: $195MQ3 ’19: $147MQ4 ’19: $132MQ4 ’19Q1 ’20: $108MQ2 ’20: $121MQ3 ’20: $137MQ4 ’20: $157MQ4 ’20Q1 ’21: $135MQ2 ’21: $141MQ3 ’21: $151MQ4 ’21: $126MQ4 ’21Q1 ’22: $157MQ2 ’22: $166MQ3 ’22: $175MQ4 ’22: $168MQ4 ’22Q1 ’23: $123MQ2 ’23: $219MQ3 ’23: $216MQ4 ’23: $276MQ4 ’23Q1 ’24: $280MQ2 ’24: $274MQ3 ’24: $290MQ4 ’24: $269MQ4 ’24Q1 ’25: $260MQ2 ’25: $272MQ3 ’25: $408MQ4 ’25: $388MQ4 ’25Q1 ’26: $362Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 67.6%Other: 19.0%ADR: 10.8%ETP: 2.5%REIT: 0.1%
  • Common Stock · 67.6% · $95M
  • Other · 19.0% · $27M
  • ADR · 10.8% · $15M
  • ETP · 2.5% · $4M
  • REIT · 0.1% · $85,000

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IHS MARKIT LTDNEW+32.7K32.7K+$4M$4M
NUANEURNUANCE COMMUNICATIONS INCNEW+64.8K64.8K+$4M$4M
CATALYST PARTNRS ACQUISITN CNEW+200.0K200.0K+$2M$2M
JUST EAT TAKEAWAY COM N VNEW+93.6K93.6K+$2M$2M
PTGXPROTAGONIST THERAPEUTICS INCNEW+25.9K25.9K+$1M$1M
MCRB1EURSERES THERAPEUTICS INCNEW+44.8K44.8K+$1M$1M
MORFUSDMORPHIC HLDG INCNEW+17.9K17.9K+$1M$1M
VTGNUSDVISTAGEN THERAPEUTICS INCNEW+308.1K308.1K+$971,000$971,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1DELLDELL TECHNOLOGIES INChistory →CL C25.13%$35M355.4K
2WILLIS TOWERS WATSON PLC LTDSHS6.70%$9M41.1K
3BABAALIBABA GROUP HLDG LTDhistory →SPONSORED ADS4.19%$6M26.1K
4MSD ACQUISITION CORPUNIT 03/25/20263.58%$5M500.0K
5MXIMMAXIM INTEGRATED PRODS INChistory →COM3.18%$4M42.6K
6ALXNALEXION PHARMACEUTICALS INChistory →COM2.80%$4M21.5K
7IHS MARKIT LTDSHS2.62%$4M32.7K
8WORKSLACK TECHNOLOGIES INChistory →COM CL A2.53%$4M80.6K
9NUANEURNUANCE COMMUNICATIONS INChistory →COM2.50%$4M64.8K
10XLNXEURXILINX INChistory →COM2.48%$3M24.2K
11SOGOGBPSOGOU INChistory →ADR REPSTG A2.18%$3M360.0K
12ISHARES TRMSCI INDIA SM CP1.91%$3M49.4K
13CATALYST PARTNRS ACQUISITN CUNIT 99/99/99991.43%$2M200.0K
14ATHMAUTOHOME INChistory →SP ADS RP CL A1.40%$2M31.0K
15JUST EAT TAKEAWAY COM N VSPONSORED ADS1.21%$2M93.6K
16DOUYU INTL HLDGS LTDSPONSORED ADS1.21%$2M249.6K
17PTGXPROTAGONIST THERAPEUTICS INCCOM0.82%$1M25.9K
18TCE2CELLDEX THERAPEUTICS INC NEWCOM NEW0.80%$1M33.9K
19NVV1NOVAVAX INCCOM NEW0.77%$1M5.1K
20MCRB1EURSERES THERAPEUTICS INCCOM0.76%$1M44.8K
21MORFUSDMORPHIC HLDG INCCOM0.73%$1M17.9K
22VTGNUSDVISTAGEN THERAPEUTICS INCCOM NEW0.69%$971,000308.1K
23FATEFATE THERAPEUTICS INCCOM0.69%$966,00011.1K
24NKTXNKARTA INCCOM0.68%$964,00030.4K
25TREURTRILLIUM THERAPEUTICS INCCOM NEW0.65%$916,00094.5K
26INVITAE CORPCOM0.64%$906,00026.9K
27KYMRKYMERA THERAPEUTICS INCCOM0.64%$901,00018.6K
28ZYMEUSDZYMEWORKS INCCOM0.63%$883,00025.5K
29ARGXARGENX SESPONSORED ADR0.62%$879,0002.9K
30SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.62%$876,00010.6K
31OCULOCULAR THERAPEUTIX INCCOM0.62%$875,00061.6K
321K0IGM BIOSCIENCES INCCOM0.62%$872,00010.5K
33BIDUNBAIDU INCSPON ADR REP A0.61%$858,0004.2K
34RLAYRELAY THERAPEUTICS INCCOM0.60%$851,00023.3K
35IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.60%$845,00032.5K
36CCCCC4 THERAPEUTICS INCCOM STK0.58%$822,00021.7K
37SNDXSYNDAX PHARMACEUTICALS INCCOM0.58%$821,00047.8K
38DBCINVESCO DB COMMDY INDX TRCKUNIT0.58%$816,00042.4K
39RCKTROCKET PHARMACEUTICALS INCCOM0.58%$816,00018.4K
40OLMAOLEMA PHARMACEUTICALS INCCOM0.58%$815,00029.1K
41MERSANA THERAPEUTICS INCCOM0.58%$814,00059.9K
42AM6AMICUS THERAPEUTICS INCCOM0.58%$813,00084.4K
43HORIZON THERAPEUTICS PUB LSHS0.58%$813,0008.7K
44PMVPPMV PHARMACEUTICALS INCCOM0.58%$812,00023.8K
45INSTIL BIO INCCOM0.57%$801,00041.4K
46AVIRATEA PHARMACEUTICALS INCCOM0.57%$801,00037.3K
47KURAKURA ONCOLOGY INCCOM0.57%$801,00038.4K
48SPRYSILVERBACK THERAPEUTICS INCCOM0.57%$800,00025.9K
49ASCENDIS PHARMA A/SSPONSORED ADR0.57%$797,0006.1K
50BBIOBRIDGEBIO PHARMA INCCOM0.56%$796,00013.1K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$362M156May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$388M145Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$408M148Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$272M146Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$260M148May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$269M137Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$290M142Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$274M138Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$280M131May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$276M126Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$216M132Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$219M134Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$123M108May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$168M105Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$175M113Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$166M110Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$157M86May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$126M69Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$151M127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$141M116Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$135M125May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$157M117Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$137M113Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$121M100Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$108M65May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M119Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$147M126Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$195M108Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$123M112May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$116M113Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.